Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Lowered by Leerink Partnrs
Leerink Partnrs downgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from a strong-buy rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports. Several other brokerages have also issued reports on RGLS. Canaccord Genuity Group reiterated a “hold” rating and issued a $11.00 price target (down previously from $28.00) on shares […]
Leerink Partnrs downgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from a strong-buy rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports. Several other brokerages have also issued reports on RGLS. Canaccord Genuity Group reiterated a “hold” rating and issued a $11.00 price target (down previously from $28.00) on shares […]
